Trevi Therapeutics, Inc.
TRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563880
In the last 90 days, Trevi Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 218 institutions reported holding it in 13F filings for Q2 2026, worth $2.76B in total; Viking Global Investors is the only superinvestor holding it.
Q3 2022 vs. Q2 2022
How the institutions holding Trevi Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 32 | 40 | +8 |
| Shares | 28.8M | 45.8M | +17.0M (+59.2%) |
| Value | $80.8M | $70.5M | −$10.3M (−12.7%) |
New holders (11)
Institutions that held Trevi Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Viking Global Investors LPSuperinvestorViking Global Investors | 4,400,000 | $6.78M | 0.03% |
| Silverarc Capital Management, LLC | 939,265 | $1.45M | 0.61% |
| Morgan Stanley | 428,405 | $660.0K | 0.00% |
| Marshall Wace, LLP | 128,324 | $198.0K | 0.00% |
| Hillsdale Investment Management Inc. | 86,531 | $133.0K | 0.01% |
| Two Sigma Investments, LP | 79,437 | $122.0K | 0.00% |
| Jump Financial, LLC | 42,977 | $66.0K | 0.00% |
| Bank of New York Mellon Corp | 14,098 | $22.0K | 0.00% |
| Credit Suisse AG | 10,374 | $16.0K | 0.00% |
| Federated Hermes, Inc. | 872 | $1.00K | 0.00% |
| Royal Bank of Canada | 149 | $0 | 0.00% |
Sold out (3)
Institutions that held Trevi Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| FNY Investment Advisers, LLC | 7,986 | $22.0K |
| Citigroup Inc | 1,700 | $5.00K |
| Curi Capital | 998 | $3.00K |